| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| NovaBridge Biosciences | Lemzoparlimab with Vidaza (Azacitidine) | Acute Myeloid Leukemia / Myelodysplastic Syndrome | Phase 3 | Ongoing | Intravenous and subcutaneous | Oncology |
| NovaBridge Biosciences | Eftansomatropin (TJ101) - (TALLER) | Growth hormone deficiency | Phase 3 | Trial Completed | Subcutaneous | Growth Disorder |
| NovaBridge Biosciences | Felzartamab (TJ202/MOR202) | Multiple Myeloma (MM) - second line | Phase 3 | Ongoing | Intravenous | Oncology |
| NovaBridge Biosciences | Efineptakin alfa (TJ107) | Solid tumors | Phase 2 | Ongoing | Subcutaneous | Oncology |
| NovaBridge Biosciences | Enoblituzumab (TJ271) and KEYTRUDA (pembrolizumab) | Solid tumors | Phase 2 | Trial Planned | Intravenous | Oncology |
| NovaBridge Biosciences | Efineptakin alfa (TJ107) | Glioblastoma multiforme (GBM) | Phase 2 | Trial Completed | Subcutaneous | Oncology |
| NovaBridge Biosciences | Olamkicept (TJ301) | Ulcerative colitis | Phase 2 | Trial Planned | Intravenous | Gastroenterology |
| NovaBridge Biosciences | Enoblituzumab (TJ271) and KEYTRUDA (pembrolizumab) | Solid tumors | Phase 2 | Trial Planned | Intravenous | Oncology |